NGM · Biotechnology

EyePoint, Inc. (EYPT) Stock

$0.40 -5.51% NGM: EYPT Healthcare

Valuation

MetricValue
Price$0.40
Market Cap$33.91M
P/E Ratio-0.91
P/B Ratio1.78
P/S Ratio102.81
EPS (TTM)$-3.17
52-Week High$19.11
52-Week Low$0.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-135.81%
ROA-134.38%
ROCE-170.19%
Gross Margin-787.10%
Operating Margin-783.87%
Net Margin-748.39%
Debt/Equity0.13
Current Ratio8.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$37.0M$41.0M$46.0M$43.0M$31.0M
Operating Profit$-55.0M$-100.0M$-75.0M$-146.0M$-243.0M
Net Profit$-58.0M$-102.0M$-71.0M$-131.0M$-232.0M
EPS$-2.03$-2.74$-1.82$-2.32$-3.17
Op Margin-149.6%-240.7%-163.1%-337.1%-776.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$263.0M$180.0M$355.0M$418.0M$364.0M
Total Liabilities$79.0M$84.0M$89.0M$82.0M$58.0M
Cash$179.0M$96.0M$281.0M$100.0M$102.0M
Borrowings$39.0M$46.0M$5.0M$22.0M$23.0M

Latest News

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire · Jul 16, 2026 EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer GlobeNewswire · Jul 13, 2026 Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks Insider Monkey · Jul 7, 2026 EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears MarketBeat · May 26, 2026 How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets Simply Wall St. · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-50.0M$-65.0M$2.0M$-126.0M$-240.0M
Investing Cash Flow$-33.0M$-19.0M$-7.0M$-223.0M$65.0M
Financing Cash Flow$0$-3.0M$1.0M$1.0M$-1.0M
Net Cash Flow$134.0M$-83.0M$186.0M$-182.0M$2.0M
Free Cash Flow$-50.0M$-67.0M$-2.0M$-130.0M$-243.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA-0.67
FCF Yield-94.61%
Quick Ratio4.46
Interest Coverage—
Return 1Y16.54%
Return 3Y18.99%
Return 5Y79.95%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAXBicara Therapeutics Inc. $17.07 -3.07% -6.02 $1.13B 0.00%
KODKodiak Sciences Inc $87.63 +2.16% -22.54 $5.51B 0.00%
KURAKura Oncology, Inc. $9.61 -2.54% -3.16 $854.91M 0.00%
NRIXNurix Therapeutics, Inc. $25.34 -0.67% -6.61 $2.77B 0.00%
PRMEPrime Medicine, Inc. $3.67 -1.61% -2.84 $665.65M 0.00%

About EyePoint, Inc.

EyePoint, Inc. is led by CEO Jay S. Duker, employs 165 people, headquartered in US, publicly traded since 2005.

EyePoint, Inc. (EYPT) stock trades at $0.40 with a market capitalization of $33.91M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.91, reflecting a net loss over the last twelve months, price-to-book of 1.78, price-to-sales of 102.81. Over the past 52 weeks the stock has ranged between $0.39 and $19.11, and currently trades 97.9% below its 52-week high.

On profitability, EyePoint, Inc. generates a return on equity (ROE) of -135.81% (negative, reflecting a net loss), return on capital employed of -170.19%, an operating margin of -783.87%, a net profit margin of -748.39%.

EyePoint, Inc. by the numbers, 2016–2025

Between 2016 and 2025 EyePoint, Inc. reported revenue of $8.0M rising to $31.0M, a change of +287.5% across 10 years. Compounded, revenue has grown -1.8% a year over five years, -8.9% over three, -27.9% over the last twelve months. Net profit fell to $-232.0M.

Operating margin went from -240.1% in 2016 to -776.0% in 2025, a fall of 535.8 percentage points. The most recent net margin is -748.39%. On a trailing twelve-month basis to Jun '26, revenue is $4.0M and net profit $-307.0M.

Borrowings stand at $23.0M, cash from operations was $-240.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -55.8% over five years, and was -75.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

EyePoint, Inc. (EYPT) — frequently asked questions

What is EyePoint, Inc. (EYPT) stock price today?

EyePoint, Inc. (EYPT) is currently trading at $0.40, down 5.51% today.

What is EYPT P/E ratio?

EyePoint, Inc.'s P/E ratio is -0.91. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is EYPT return on equity (ROE)?

EyePoint, Inc.'s return on equity (ROE) is -135.81%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is EyePoint, Inc.'s market cap?

EyePoint, Inc. has a market capitalization of $33.91M.

Does EYPT pay a dividend?

EyePoint, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does EYPT carry?

EyePoint, Inc. has a debt-to-equity ratio of 0.13. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is EYPT's profit margin?

EyePoint, Inc. reports a net profit margin of -748.39% — the share of revenue left after every cost, including tax and interest.

What sector is EYPT in?

EyePoint, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is EYPT listed on?

EyePoint, Inc. trades on NGM under the ticker EYPT.

What is EYPT's 52-week range?

Over the last year EyePoint, Inc. has traded between $0.39 and $19.11.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens EYPT currently matches

On the figures above, EyePoint, Inc. passes the filters for 4 of our ready-made screens, among them Day Losers Stocks, Penny Stocks, Stocks Under $1. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Day Losers StocksPenny StocksStocks Under $1Nano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.